why choose us

First received: October 18, 2023

Clinical Trial: A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Brief Summary: The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.

Read more